Skip to main content
  • Immunotherapy
    in Actions
    The new wave of immunotherapy antibodies in cancers and rare haematological diseases
  • ElsaLys Biotech
    A clinical stage immuno-oncology company that designs and develops
    a new generation of therapeutic antibodies

Welcome to ElsaLys Biotech

ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.

Today ELSALYS BIOTECH is conducting 4 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.

The company is acting today in 3 main medical fields :

New Updates

Discover our latest news regarding our pipeline, our partnerships and more

Wed, 05/08/2019 - 08:00

In 2015, the single interministerial fund (FUI) approved the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project, led by a consortium o

Mon, 02/18/2019 - 08:46 - Tue, 02/01/2022 - 09:00

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)


Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.